Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3899065 | 0.95 | ADRB2 (0.38) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL11615347 | 0.90 | THRB (0.38) | ALDH1A1TSHRCA1CA2 | |
| SCHEMBL9329827 | 0.90 | THRB (0.38) | ALDH1A1TSHRCA1CA2 | |
| SCHEMBL9329868 | 0.90 | THRB (0.38) | ALDH1A1TSHRCA1CA2 | |
| SCHEMBL7068263 | 0.87 | CA1 (0.33) | TSHRCA1CA2HCAR2 | |
| SCHEMBL11416118 | 0.85 | THRB (0.38) | ALDH1A1TSHRCA1CA2 | |
| SCHEMBL11208522 | 0.85 | THRB (0.38) | ALDH1A1TSHRCA1CA2 | |
| SCHEMBL8650965 | 0.83 | ALDH1A1 (0.43) | ADRB2ADRB1ADRB3ALDH1A1TSHR | |
| SCHEMBL5068846 | 0.83 | ALDH1A1 (0.36) | ALDH1A1TP53 | |
| SCHEMBL9719492 | 0.83 | ADRB2 (0.45) | ADRB2ADRB1ADRB3ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4242479-A | CATALYST OF ALUMINUM TRIHALIDE, ORGANOSILOXANE COMPOUND OR ETHER, MAGNESIUM ALCOHOLATE, TITANIUM-HALOGEN AND ORGANOALUMINUM COMPOUNDS | SHOWA YUKA KABUSHIKI KAISHA (JP) | 1980-12-30 | — | — | US | claimed |
| CN-112028936-A | Purification method of methyl phosphonous acid dialkyl ester | 河北威远生物化工有限公司 | 2020-12-04 | — | — | CN | disclosed |
| EP-1882694-B1 | OLIGOMERS AND POLYMERS OF THIOPHENE COMPOUNDS HAVING PHOSPHORIC ESTER AND PROCESS FOR PRODUCING THE SAME | NISSAN CHEMICAL IND LTD (JP) | 2013-04-03 | — | — | EP | disclosed |
| EP-1882694-A1 | THIOPHENE COMPOUND HAVING PHOSPHORIC ESTER AND PROCESS FOR PRODUCING THE SAME | Nissan Chemical Industries, Ltd. (JP) | 2008-01-30 | — | — | EP | disclosed |
| EP-1318155-B1 | Novel asymmetric phosphine ligand | TAKASAGO PERFUMERY CO LTD (JP) | 2005-03-23 | — | — | EP | disclosed |
| WO-2005014670-A2 | METHOD FOR PREPARING CATALYST PRECURSOR CONTAINING PHOSPHATES/PHOSPHITES REAGENTS | INNOVENE EUROPE LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| EP-1502924-A1 | High activity catalysts for the polymerisation of ethylene prepared with phosphates/phosphites reagents | BP LAVERA SNC (FR) | 2005-02-02 | — | — | EP | disclosed |
| US-6624320-B2 | Phosphorane compound hydrogenation catalyts; stereospecific; catalyst selectivity | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-09-23 | — | — | US | disclosed |
| US-20030144138-A1 | NOVEL ASYMMETRIC PHOSPHINE LIGAND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1318155-A1 | Novel asymmetric phosphine ligand | Takasago International Corporation (JP) | 2003-06-11 | — | — | EP | disclosed |
| US-4242479-A | CATALYST OF ALUMINUM TRIHALIDE, ORGANOSILOXANE COMPOUND OR ETHER, MAGNESIUM ALCOHOLATE, TITANIUM-HALOGEN AND ORGANOALUMINUM COMPOUNDS | SHOWA YUKA KABUSHIKI KAISHA (JP) | 1980-12-30 | — | — | US | disclosed |
| US-4028481-A | ACTIVATED TITANIUM TRICHLORIDE AND AN ORGANOALUMINUM COMPOUND | MITSUI TOATSU CHEMICALS, INCORPORATED (JA) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144138-A1 | NOVEL ASYMMETRIC PHOSPHINE LIGAND | PHOSPHO1, PLCG2, PLCB3 | ADRB2 775/4885ADRB1 1110/4885ADRB3 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.